Abbott Laboratories is a dividend growth machine that's known for consistency. AbbVie's dividend has more than quadrupled ...

Today's rally followed Glenmark's Thursday announcement that its innovation arm, Ichnos Glenmark Innovation (IGI), has entered into an exclusive global licensing deal with US-based AbbVie.

AbbVie is taking a different tact with Skyrizi’s TV ads when compared to its other autoimmune drug Rinvoq.

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

During periods of market volatility and economic uncertainty, investors often look for refuge in dependable, dividend-paying ...

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside. Read why ABBV stock is a hold.

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more long-term promise.

The FDA has scolded AbbVie for making false and misleading claims about a TV ad about a migraine pill that features Serena Williams.

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April, according to data released by iSpot.tv on Wednesday afternoon.